Therapy News and Research

RSS

Research sheds light on how hypoxia affects T cell function in cancer

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes, or TILs, ineffective.

14 Dec 2024

Research finds no change in mortality despite platinum chemotherapy shortage

During a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023, there was no difference in mortality rates among patients with advanced cancer compared to the previous year, and prescription rates for the two drugs fell less than three percent overall - and 15.1 percent at the peak - according to an analysis published this week in the Journal of the National Cancer Institute by researchers from the University of Pennsylvania's Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

14 Dec 2024

Dietary adjustments may help control prostate cancer in men undergoing active surveillance

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators offers new evidence that dietary changes may help reduce cancer cell growth in patients undergoing active surveillance, a treatment approach that involves regular monitoring of the cancer without immediate intervention.

14 Dec 2024

Promising combination therapy could improve liver cancer outcomes

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, "Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma."

14 Dec 2024

Scientists reveal the spread of highly drug-resistant cholera strain

Scientists from the National Reference Center for Vibrios and Cholera at the Institut Pasteur, in collaboration with the Centre hospitalier de Mayotte, have revealed the spread of a highly drug-resistant cholera strain.

14 Dec 2024

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Targeted gene therapy shuts down cancer cells' energy centers

Researchers are shining a light on cancer cells' energy centers – literally – to damage these power sources and trigger widespread cancer cell death.

14 Dec 2024

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Cardio-oncology experts highlight importance of heart health in cancer care

The devastating news of a cancer diagnosis understandably makes doctors and patients focus on the cancer itself.

13 Dec 2024

Study highlights the impact of Reiki on pain, fatigue, and anxiety in cancer outpatients

A recent study conducted at University Hospitals Connor Whole Health has evaluated a Reiki program designed for outpatients with cancer and receiving infusion treatments at two University Hospitals infusion centers.

13 Dec 2024

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and potential therapeutic strategies.

13 Dec 2024

Potential new mRNA-based therapy for pre-eclampsia

Lipid nanoparticles targeting VEGF mRNA show promise in treating pre-eclampsia, restoring maternal blood pressure and enhancing fetal health in murine models.

13 Dec 2024

Key to LDL clearance uncovered: Structural details of apoB100-LDLR binding emerge

Researchers reveal the structural details of apoB100's interaction with LDL receptors, offering insights into LDL dimerization and potential treatments for familial hypercholesterolemia.

12 Dec 2024

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

Therapy News and Research

Research sheds light on how hypoxia affects T cell function in cancer

Research finds no change in mortality despite platinum chemotherapy shortage

Dietary adjustments may help control prostate cancer in men undergoing active surveillance

Promising combination therapy could improve liver cancer outcomes

Scientists reveal the spread of highly drug-resistant cholera strain

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

Targeted gene therapy shuts down cancer cells' energy centers

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Cardio-oncology experts highlight importance of heart health in cancer care

Study highlights the impact of Reiki on pain, fatigue, and anxiety in cancer outpatients

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

Potential new mRNA-based therapy for pre-eclampsia

Key to LDL clearance uncovered: Structural details of apoB100-LDLR binding emerge

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News